-$0.22 EPS Expected for Achieve Life Sciences Inc (NASDAQ:ACHV) This Quarter

Wall Street brokerages expect Achieve Life Sciences Inc (NASDAQ:ACHV) to post earnings per share (EPS) of ($0.22) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Achieve Life Sciences’ earnings. Achieve Life Sciences posted earnings per share of ($0.71) during the same quarter last year, which would indicate a positive year-over-year growth rate of 69%. The company is scheduled to announce its next quarterly earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that Achieve Life Sciences will report full-year earnings of ($1.60) per share for the current financial year, with EPS estimates ranging from ($1.83) to ($1.36). For the next financial year, analysts expect that the company will post earnings of ($1.49) per share, with EPS estimates ranging from ($1.82) to ($1.16). Zacks’ EPS calculations are a mean average based on a survey of analysts that follow Achieve Life Sciences.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.17).

Several equities research analysts recently weighed in on the stock. LADENBURG THALM/SH SH restated a “buy” rating and issued a $20.00 price target on shares of Achieve Life Sciences in a research report on Friday, August 9th. Maxim Group set a $6.00 price target on shares of Achieve Life Sciences and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, ValuEngine upgraded shares of Achieve Life Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.

In other news, major shareholder Armistice Capital Master Fund acquired 12,813 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were acquired at an average price of $3.80 per share, for a total transaction of $48,689.40. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.80% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in Achieve Life Sciences during the second quarter valued at $32,000. Searle & CO. increased its position in Achieve Life Sciences by 80.4% during the second quarter. Searle & CO. now owns 132,592 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 59,092 shares during the last quarter. Vanguard Group Inc. increased its position in Achieve Life Sciences by 152.2% during the second quarter. Vanguard Group Inc. now owns 274,519 shares of the biopharmaceutical company’s stock valued at $530,000 after acquiring an additional 165,667 shares during the last quarter. Renaissance Technologies LLC increased its position in Achieve Life Sciences by 12.5% during the second quarter. Renaissance Technologies LLC now owns 321,268 shares of the biopharmaceutical company’s stock valued at $620,000 after acquiring an additional 35,607 shares during the last quarter. Finally, Sio Capital Management LLC increased its position in Achieve Life Sciences by 24.4% during the second quarter. Sio Capital Management LLC now owns 524,413 shares of the biopharmaceutical company’s stock valued at $1,012,000 after acquiring an additional 102,934 shares during the last quarter. Institutional investors and hedge funds own 15.66% of the company’s stock.

ACHV traded down $0.04 during trading hours on Friday, hitting $1.94. The company’s stock had a trading volume of 160,393 shares, compared to its average volume of 83,593. The business’s 50-day moving average price is $1.84 and its 200-day moving average price is $2.77. Achieve Life Sciences has a 12 month low of $1.04 and a 12 month high of $5.25. The stock has a market cap of $16.03 million, a price-to-earnings ratio of -0.54 and a beta of 2.07. The company has a current ratio of 3.62, a quick ratio of 3.62 and a debt-to-equity ratio of 0.02.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.

Recommended Story: Quick Ratio

Get a free copy of the Zacks research report on Achieve Life Sciences (ACHV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.